mRNA -1215 for Nipah Virus Infection

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
National Institutes of Health Clinical Center, Bethesda, MD
Nipah Virus Infection+1 More
mRNA -1215 - Biological
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the safety of an experimental vaccine for Nipah virus. The virus is transmitted from animals to humans, and can cause serious symptoms like brain inflammation and death. There is no cure. The mRNA-1215 drug is being used to treat patients with the Nipah virus infection. This drug has already been approved by the FDA for another condition. The treatment is free for patients in this clinical trial. All patients in this trial will receive the active drug, and there will be no placebo group.

Eligible Conditions

  • Nipah Virus Infection

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Nipah Virus Infection

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: 2 weeks after last product administration

Week 2
To evaluate antibody responses to the mRNA-1215 vaccine
Week 52
To evaluate the safety and tolerability of a 2-dose vaccine regimen of mRNA-1215
To evaluate the safety and tolerability of a 2-dose vaccine regimen of mRNA-1215, given in a 4-week interval
To evaluate the safety and tolerability of a 2-dose vaccine regimen of mRNA-1215, given in a 4-week interval.

Trial Safety

Safety Progress

1 of 3

Other trials for Nipah Virus Infection

Trial Design

4 Treatment Groups

Group 4
1 of 4
Group 3
1 of 4
Group 2
1 of 4
Group 1
1 of 4
Experimental Treatment

50 Total Participants · 4 Treatment Groups

Primary Treatment: mRNA -1215 · No Placebo Group · Phase 1

Group 4
Biological
Experimental Group · 1 Intervention: mRNA -1215 · Intervention Types: Biological
Group 3
Biological
Experimental Group · 1 Intervention: mRNA -1215 · Intervention Types: Biological
Group 2
Biological
Experimental Group · 1 Intervention: mRNA -1215 · Intervention Types: Biological
Group 1
Biological
Experimental Group · 1 Intervention: mRNA -1215 · Intervention Types: Biological

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 weeks after last product administration
Closest Location: National Institutes of Health Clinical Center · Bethesda, MD
Photo of maryland 1Photo of maryland 2Photo of maryland 3
2016First Recorded Clinical Trial
1 TrialsResearching Nipah Virus Infection
277 CompletedClinical Trials

Who is running the clinical trial?

Moderna TX, IncUNKNOWN
National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor
3,109 Previous Clinical Trials
4,671,237 Total Patients Enrolled
Alicia T Widge, M.D.Principal InvestigatorNational Institute of Allergy and Infectious Diseases (NIAID)
3 Previous Clinical Trials
112 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a healthy adult between the ages of 18-60 years inclusive.
You have no history of any of the conditions listed in the table.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.